Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome.

Autor:in

Slavic, Svetlana; Lauer, Dilyara; Sommerfeld, Manuela; Kemnitz, Ulrich Rudolf; Grzesiak, Aleksandra; Trappiel, Manuela; Thöne-Reineke, Christa; Baulmann, Johannes; Paulis, Ludovit; Kappert, Kai; Kintscher, Ulrich; Unger, Thomas; Kaschina, Elena;

Schlagwörter

Animals; Cannabinoid Receptor Antagonists/pharmacology; Cannabinoid Receptor Antagonists/therapeutic use*; Cardiotonic Agents/pharmacology; Cardiotonic Agents/therapeutic use*; Cells, Cultured; Collagen/metabolism; Fibroblasts/drug effects; Fibroblasts/metabolism; Heart/drug effects; Heart/physiology; Male; Matrix Metalloproteinase 2/metabolism; Matrix Metalloproteinase 9/metabolism; Metabolic Syndrome X/drug therapy*; Metabolic Syndrome X/physiopathology; Myocardial Infarction/drug therapy*; Myocardial Infarction/physiopathology; Piperidines/therapeutic use*; Pyrazoles/therapeutic use*; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1/antagonists & inhibitors*; Transforming Growth Factor beta1/metabolism;

ISSN/eISSN

0946-2716 -

WoS ID

WOS:000321129300005